当前位置: X-MOL 学术Anti-Cancer Drugs › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anti-Cancer Drugs ( IF 2.3 ) Pub Date : 2021-08-16 , DOI: 10.1097/cad.0000000000001209
Emilia Montagna 1 , Eleonora Pagan 2 , Giuseppe Cancello 1 , Claudia Sangalli 3 , Vincenzo Bagnardi 2 , Elisabetta Munzone 1 , Emanuela Omodeo Salè 4 , Daniela Malengo 4 , Marina Elena Cazzaniga 5 , Mara Negri 3 , Giulia Peruzzotti 3 , Paolo Veronesi 6, 7, 8 , Giuseppe Viale 7, 8 , Marco Colleoni 1
Affiliation  

Metronomic chemotherapy is a treatment option for metastatic breast cancer (MBC) patients who require prolonged disease control without cumulative toxicity. Data available on the efficacy and tolerability of prolonged usage of metronomic therapy are limited.

中文翻译:

节拍化疗(VEX 方案)对转移性乳腺癌患者的长期临床益处。

节律化疗是转移性乳腺癌 (MBC) 患者的一种治疗选择,这些患者需要长期疾病控制且无累积毒性。关于长期使用节拍疗法的疗效和耐受性的可用数据有限。
更新日期:2021-08-16
down
wechat
bug